CA2134670A1 - Systeme de vecteur epidermique constitutif et inductible - Google Patents

Systeme de vecteur epidermique constitutif et inductible

Info

Publication number
CA2134670A1
CA2134670A1 CA002134670A CA2134670A CA2134670A1 CA 2134670 A1 CA2134670 A1 CA 2134670A1 CA 002134670 A CA002134670 A CA 002134670A CA 2134670 A CA2134670 A CA 2134670A CA 2134670 A1 CA2134670 A1 CA 2134670A1
Authority
CA
Canada
Prior art keywords
nucleic acid
vector
cassette
acid sequence
epidermal cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002134670A
Other languages
English (en)
Inventor
Dennis R. Roop
Joseph A. Rothnagel
David A. Greenhalgh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2134670A1 publication Critical patent/CA2134670A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
CA002134670A 1992-04-30 1993-04-28 Systeme de vecteur epidermique constitutif et inductible Abandoned CA2134670A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87628692A 1992-04-30 1992-04-30
US07/876,286 1992-04-30

Publications (1)

Publication Number Publication Date
CA2134670A1 true CA2134670A1 (fr) 1993-11-11

Family

ID=25367356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002134670A Abandoned CA2134670A1 (fr) 1992-04-30 1993-04-28 Systeme de vecteur epidermique constitutif et inductible

Country Status (5)

Country Link
EP (1) EP0644933A4 (fr)
JP (1) JPH08501202A (fr)
AU (1) AU669713B2 (fr)
CA (1) CA2134670A1 (fr)
WO (1) WO1993022431A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152753B1 (es) * 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
AUPM746694A0 (en) * 1994-08-15 1994-09-08 Garvan Institute Of Medical Research Expression vector
AU698317B2 (en) * 1995-02-25 1998-10-29 Cancer Research Technology Limited Transgenic animals as model of psoriasis
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US7094766B1 (en) 1995-06-06 2006-08-22 Trustees Of Boston University Use of locally applied DNA fragments
US5955059A (en) * 1995-06-06 1999-09-21 Trustees Of Boston University Use of locally applied DNA fragments
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
EP2363133A1 (fr) 2000-03-31 2011-09-07 Trustees of Boston University Formulation comprenant des fragments d' ADN et utilisations médicales et cosmétiques de celle-ci
DK3079712T3 (da) 2013-12-11 2022-04-25 Massachusetts Gen Hospital Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
ATE79138T1 (de) * 1985-04-04 1992-08-15 Univ Georgetown Typenspezifische papillomavirus-dns-sequenzen und peptide.
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4816464A (en) * 1987-06-22 1989-03-28 American Home Products Corporation 10-Substituted benzo[b][1,6]naphthyridines as inhibitors of interleukin 1
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
JPH02109966A (ja) * 1988-10-20 1990-04-23 Kirin Brewery Co Ltd ラジアルフロー式充填層型バイオリアクタ
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides

Also Published As

Publication number Publication date
WO1993022431A1 (fr) 1993-11-11
EP0644933A4 (fr) 1997-06-25
AU669713B2 (en) 1996-06-20
EP0644933A1 (fr) 1995-03-29
AU4221393A (en) 1993-11-29
JPH08501202A (ja) 1996-02-13

Similar Documents

Publication Publication Date Title
RU2767201C2 (ru) Искусственная модификация генома для регуляции экспрессии гена
KR101627917B1 (ko) Cpne7 단백질을 포함하는 비치계 중간엽 줄기세포의 상아모세포로의 분화방법, 조성물 및 이를 이용한 치수조직 재생 및 상아질 지각과민증 치료용 약학적 조성물
CN109072255A (zh) 用于治疗皮肤的伤口、病症和疾病的组合物和方法
AU2017337147A1 (en) Modified stem cell memory T cells, methods of making and methods of using same
JPH06508025A (ja) 癌胎児性抗原を発現する組換えウイルスとその使用方法
CA3091912A1 (fr) Methodes et compositions de traitement du syndrome d'angelman
JPH11511139A (ja) ヒツジアデノウイルスベクターを用いた遺伝子治療
CA2134670A1 (fr) Systeme de vecteur epidermique constitutif et inductible
AU2018200078A1 (en) Mitigating Tissue Damage and Fibrosis Via Latent Transforming Growth Factor Beta Binding Protein (LTBP4)
FR2717824A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA3224970A1 (fr) Compositions et procedes d'edition de genome efficace
CA2522994A1 (fr) Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer
KR20230003511A (ko) 안면견갑상완 근이영양증에 대한 crispr-억제
EP0811071B1 (fr) Sequences amplificatrices derivees du gene de la desmine, vecteurs portant ces sequences et leurs utilisations pour la production de proteines
Kato et al. Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve
US5460951A (en) Bone-related carboxypeptidase-like protein and process for its production
Zhao et al. Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent
Andreadis Gene transfer to epidermal stem cells: implications for tissue engineering
US20230295658A1 (en) Compositions and methods for in vivo gene transfer
US20030077757A1 (en) Method of treating aging-related disorders
KR102460983B1 (ko) 새로운 재생 치료제로서의 camkk1
CA2440461A1 (fr) Acide nucleique et proteine correspondante, designe par 161p5c5, utilise dans le traitement et la detection du cancer
CA2250099A1 (fr) Sequences en amont du gene sm22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
WO2020132226A1 (fr) Compositions et méthodes pour reprogrammer des cellules musculo-squelettiques malades
CN114615985A (zh) 包含修饰mRNA的分子的组合物及其使用方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead